New stable synthetic bacteriochlorins for photodynamic therapy of melanoma

Pawel Mroz, Ying Ying Huang, Sahar Janjua, Timur Zhiyentayev, Christian Ruzié, K. Eszter Borbas, Dazhong Fan, Michael Krayer, Thiagarajan Balasubramanian, Eun Kyung Yang, Hooi Ling Kee, Dewey Holten, Jonathan S. Lindsey, Michael R. Hamblin

Research output: Chapter in Book/Report/Conference proceedingConference contribution

6 Scopus citations

Abstract

Photodynamic therapy (PDT) has been successfully used to treat many malignancies, and has afforded highly encouraging results in skin cancers such as basal cell carcinoma. However, pigmented melanoma remains a notable exception from the range of tumors treated by PDT largely due to the fact that melanin has high absorption of light in wavelength regions where most clinically approved photosensitizers (PS) absorb light (600-690 nm). Moreover, melanoma cells sequester exogenous molecules including photosensitizers inside melanosomes. The aforementioned drawbacks of the clinically used PS have motivated us to search for new classes of PS with improved spectral properties, such as bacteriochlorins (BC) to be used in PDT of melanoma. To overcome the PDT-resistance mechanisms of melanoma, particularly the high optical absorption of melanin, three near-infrared (NIR) absorbing synthetic stable BC were used in PDT treatment of melanoma. Dose and fluence dependent cell killing, intracellular localization (particularly in melanosomes), and correlation between the melanin level and cell death were examined. Intracellular melanosomes are ruptured after illumination as shown by electron microscopy. The best in vitro performing BC were tested upon delivery in micellar nanoparticles against a mouse pigmented melanoma. Two of the BC were effective at significantly lower concentrations (<0.5 μM) than common photosensitizers in present use.

Original languageEnglish (US)
Title of host publication12th World Congress of the International Photodynamic Association - Photodynamic Therapy
Subtitle of host publicationBack to the Future
DOIs
StatePublished - Dec 1 2009
Event12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future - Seattle, WA, United States
Duration: Jun 11 2009Jun 15 2009

Publication series

NameProgress in Biomedical Optics and Imaging - Proceedings of SPIE
Volume7380
ISSN (Print)1605-7422

Other

Other12th World Congress of the International Photodynamic Association - Photodynamic Therapy: Back to the Future
Country/TerritoryUnited States
CitySeattle, WA
Period6/11/096/15/09

Keywords

  • bacteriochlorins
  • melanoma
  • melanosomes
  • multidrug resistance
  • photodynamic therapy

Fingerprint

Dive into the research topics of 'New stable synthetic bacteriochlorins for photodynamic therapy of melanoma'. Together they form a unique fingerprint.

Cite this